Powered by

-TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting

Nov 20, 2018 - ENP Newswire

SAN DIEGO - TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, yesterday presented data from the Company's Phase 2 study of TRC102 and Temodar (temozolomide) in patients with recurrent glioblastoma at the Society for Neuro-Oncology (SNO) annual meeting, taking place in New Orleans.

TRC102 is a small molecule i...